sEphB4-HSA

N/A

Report date: 2024/07/11 20:00:08

Base Information

Drug NamesEphB4-HSA
Drug Alias NameEphB4-Human Serum AlbuminHuman Serum Albumin-EphB4 conjugateVas-01sEphB4-HSA
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionEphrin type-B receptor 4 antagonists
TargetsEphrin type-B receptor 4
Therapy Area/IndicationsBone metastasesSolid tumoursMyelodysplastic-Myeloproliferative Diseases +[19] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesVasgene
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Southern CaliforniaUniversity Of Colorado DenverVasgene Therapeutics Inc
Inactive CompaniesNorthwestern University
Active IndicationsUrinary Bladder NeoplasmsProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[10] 
Inactive IndicationsBone metastasesSolid tumoursMyelodysplastic-Myeloproliferative Diseases +[9] 

Other Information

ATC CodeN/A
Related LinksN/A